ECSP056025A - Compuestos glp-1 unidos a polietilenglicol - Google Patents

Compuestos glp-1 unidos a polietilenglicol

Info

Publication number
ECSP056025A
ECSP056025A EC2005006025A ECSP056025A ECSP056025A EC SP056025 A ECSP056025 A EC SP056025A EC 2005006025 A EC2005006025 A EC 2005006025A EC SP056025 A ECSP056025 A EC SP056025A EC SP056025 A ECSP056025 A EC SP056025A
Authority
EC
Ecuador
Prior art keywords
glp
compounds
polyethylene glycol
less
peg
Prior art date
Application number
EC2005006025A
Other languages
English (en)
Inventor
Richard Dennis Dimarchi
Lianshan Zhang
Wolfgang Glaesner
Rohn Lee Millican Jr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP056025A publication Critical patent/ECSP056025A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La invención descrita en este documento proporciona compuestos GLP-1 unidos covalentemente a una o más moléculas de polietilenglicol (PEG), o un derivado del mismo donde cada PEG está unido a un aminoácido Cys o Lys o al carboxi terminal del péptido, dando como resultado compuestos GLP-1 PEGilados con una semivida de eliminación de al menos una hora, preferiblemente al menos 3, 5, 7, 10, 15, 20 horas y más preferiblemente al menos 24 horas. Los compuestos GLP-1 PEGilados de la presente invención tienen preferiblemente un valor de eliminación de 200 ml/h/kg o menos, más preferiblemente 180, 150, 120, 100, 80, 60 ml/h/kg o menos y mucho más preferiblemente menos de 50, 40 o 20 ml/h/kg.
EC2005006025A 2003-03-19 2005-09-19 Compuestos glp-1 unidos a polietilenglicol ECSP056025A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45608103P 2003-03-19 2003-03-19

Publications (1)

Publication Number Publication Date
ECSP056025A true ECSP056025A (es) 2006-01-27

Family

ID=33310655

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006025A ECSP056025A (es) 2003-03-19 2005-09-19 Compuestos glp-1 unidos a polietilenglicol

Country Status (25)

Country Link
US (1) US7557183B2 (es)
EP (1) EP1605897B1 (es)
JP (1) JP2006520818A (es)
KR (1) KR100733940B1 (es)
CN (1) CN1832959A (es)
AU (1) AU2004231461B2 (es)
BR (1) BRPI0407936A (es)
CA (1) CA2518336A1 (es)
CO (1) CO5611157A2 (es)
CR (1) CR7997A (es)
CY (1) CY1114035T1 (es)
DK (1) DK1605897T3 (es)
EA (1) EA009366B1 (es)
EC (1) ECSP056025A (es)
ES (1) ES2390270T3 (es)
HR (1) HRP20050683A2 (es)
MX (1) MXPA05009940A (es)
NO (1) NO20054310L (es)
NZ (1) NZ541534A (es)
PL (1) PL1605897T3 (es)
PT (1) PT1605897E (es)
SI (1) SI1605897T1 (es)
UA (1) UA92451C2 (es)
WO (1) WO2004093823A2 (es)
ZA (1) ZA200506881B (es)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
WO2006121860A2 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
KR101011081B1 (ko) * 2005-05-13 2011-01-25 일라이 릴리 앤드 캄파니 Ｐｅｇ화된 ｇｌｐ-1 화합물
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
AU2006306236B2 (en) * 2005-10-26 2011-12-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
JP5096363B2 (ja) * 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
MX2008013304A (es) * 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN101125207B (zh) 2006-11-14 2012-09-05 上海华谊生物技术有限公司 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
EP2102355B1 (en) * 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008086086A2 (en) * 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
TWI423821B (zh) 2007-06-19 2014-01-21 Glucose-containing glucagon-like peptide-1 peptide
ES2672770T3 (es) * 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CA2702289A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
EP2217701B9 (en) 2007-10-30 2015-02-18 Indiana University Research and Technology Corporation Glucagon antagonists
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
BRPI0915282A2 (pt) * 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
IT1392655B1 (it) * 2008-11-20 2012-03-16 Bio Ker S R L Site-specific monoconjugated insulinotropic glp-1 peptides.
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
KR20110114568A (ko) * 2008-12-19 2011-10-19 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 디펩티드 링크된 약효 물질
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
EP2408800B1 (en) * 2009-03-20 2016-05-25 Hanmi Science Co., Ltd. Method for preparing a site-specific conjugate of a physiologically active polypeptide
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
EP2495255A4 (en) 2009-10-30 2013-05-15 Otsuka Chemical Co Ltd GLYCOSYLATED FORM OF AN ANTIGENIC GLP-1 ANALOG
CN104327182B (zh) 2009-12-16 2020-04-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
WO2011143788A1 (en) * 2010-05-17 2011-11-24 Zhejiang Beta Pharma Inc. Novel glucagon like peptide analogs, composition, and method of use
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CN102397558B (zh) * 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Exendin-4类似物的定位聚乙二醇化修饰物及其用途
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
CA2812102A1 (en) 2010-11-24 2012-06-07 Durect Corporation Biodegradable drug delivery composition
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
CA2821766A1 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
CN102718858B (zh) * 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
CN106928341B (zh) * 2011-03-30 2021-06-01 上海仁会生物制药股份有限公司 定点单取代聚乙二醇化Exendin类似物及其制备方法
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
CN102180963B (zh) * 2011-04-22 2014-06-25 中国药科大学 胰高血糖素样肽-1(glp-1)类似物及其应用
CN102766204B (zh) * 2011-05-05 2014-10-15 天津药物研究院 胰高血糖素样肽-1突变体多肽及其制备方法和其应用
CN102786590A (zh) * 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
EA031230B1 (ru) 2011-06-22 2018-12-28 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты глюкагонового рецептора/glp-1-рецептора
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
TW201334791A (zh) 2011-11-23 2013-09-01 杜瑞克公司 輻射滅菌之可生物降解之藥物遞送組合物
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
HRP20190489T1 (hr) 2012-03-22 2019-05-03 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
CN103087176A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087179A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087175A (zh) * 2012-11-30 2013-05-08 中国药科大学 新型长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087178A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087177A (zh) * 2012-11-30 2013-05-08 中国药科大学 一类长效化胰高血糖素样肽-1(glp-1)类似物及其应用
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
EP3010546B1 (en) 2013-06-20 2017-08-09 Novo Nordisk A/S Glp-1 derivatives and uses thereof
BR112015032875A2 (pt) 2013-07-04 2017-11-07 Novo Nordisk As derivados de peptídeos do tipo glp-1, e usos dos mesmos
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
TN2017000271A1 (en) 2014-12-30 2018-10-19 Hanmi Pharm Ind Co Ltd Glucagon derivative having improved stability
CN107708679A (zh) 2015-06-04 2018-02-16 安特里阿比奥有限公司 用于制备位点特异性蛋白质偶联物的胺聚乙二醇化方法
TN2017000555A1 (en) 2015-06-30 2019-04-12 Hanmi Pharm Ind Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
PH12018501409B1 (en) * 2015-12-31 2023-03-10 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
CN107266557B (zh) * 2016-04-06 2020-04-07 天津药物研究院有限公司 一种聚乙二醇修饰的胰高血糖素样肽-1类似物
JP7208020B2 (ja) 2016-06-29 2023-01-18 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2020115113A1 (en) 2018-12-04 2020-06-11 Københavns Universitet Dual agonist glp-1 and neurotensin fusion peptide
WO2020214012A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
US20210187077A1 (en) * 2019-12-23 2021-06-24 Idaho State University GLP-1 Agonist Conjugates for Sustained Glycemic Control
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
DE60032331T2 (de) * 1999-01-14 2007-06-21 Amylin Pharmaceuticals, Inc., San Diego Exendine zur glucagon suppression
CN1372570A (zh) * 1999-04-30 2002-10-02 安米林药品公司 修饰的exendin和exendin激动剂
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
UA93662C2 (uk) * 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
CA2455963C (en) * 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
MXPA04006679A (es) 2002-01-08 2004-11-10 Lilly Co Eli Analogos extendidos de peptido-1 de tipo glucagon.
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds

Also Published As

Publication number Publication date
NO20054310D0 (no) 2005-09-19
AU2004231461A1 (en) 2004-11-04
PT1605897E (pt) 2012-09-10
CY1114035T1 (el) 2016-07-27
SI1605897T1 (sl) 2012-11-30
AU2004231461B2 (en) 2009-11-12
MXPA05009940A (es) 2005-12-05
EP1605897A2 (en) 2005-12-21
CN1832959A (zh) 2006-09-13
UA92451C2 (en) 2010-11-10
NZ541534A (en) 2008-05-30
ES2390270T3 (es) 2012-11-08
EP1605897A4 (en) 2010-08-04
PL1605897T3 (pl) 2012-12-31
US7557183B2 (en) 2009-07-07
CR7997A (es) 2008-11-28
HRP20050683A2 (en) 2006-07-31
ZA200506881B (en) 2006-11-29
CA2518336A1 (en) 2004-11-04
DK1605897T3 (da) 2012-08-20
NO20054310L (no) 2005-11-16
WO2004093823A2 (en) 2004-11-04
KR20050111386A (ko) 2005-11-24
JP2006520818A (ja) 2006-09-14
KR100733940B1 (ko) 2007-06-29
EP1605897B1 (en) 2012-07-25
BRPI0407936A (pt) 2006-02-21
US20080113905A1 (en) 2008-05-15
CO5611157A2 (es) 2006-02-28
EA009366B1 (ru) 2007-12-28
EA200501482A1 (ru) 2006-06-30
WO2004093823A3 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
ECSP056025A (es) Compuestos glp-1 unidos a polietilenglicol
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
EP1329458A3 (en) Peptides that lower blood glucose levels
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
DE60335101D1 (de) Antimikrobielles polypeptid und nutzung davon
EP1323730A4 (en) NEW POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THEM
DeLange et al. Calf thymus histone III: Sequences of the amino-and carboxyl-terminal regions and of the regions containing lysyl residues modified by acetylation and methylation
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
ATE242202T1 (de) Peptide
WO2000058456A3 (en) Compositions and methods for modifying toxic effects of proteinacious compounds
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
DE60236330D1 (de) Biologisch aktive Peptide
ATE371737T1 (de) Proteaseresistente flint-analoge
ES2164297T3 (es) Preparacion de (poli)peptidos purificados.
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
SE9700301D0 (sv) New compound
MXPA05004849A (es) Novedosas composiciones de multiples peptidos antigenicos relacionados con inhibina, que mejoran el desempeno de produccion avicola.
MY140828A (en) Therapeutic uses of tri-, tetra-, penta-, and polypeptides